Side Effects of GB-Cita Plus:
Nausea, Diarrhoea, Increased Sweating, Insomnia, Impotence, Ejaculation Disorder, Fatigue, Somnolence; Postural Hypotension, Sinusitis, Taste Disturbances. Increased Appetite And Wt Gain.
Drug Interactions of GB-Cita Plus:
Increased Risk Of Bleeding When Used With Aspirin, NSAIDs Or Drugs That Affect Coagulation. Serum Levels May Be Reduced By CYP2C19 Inducers (E.G. Carbamazepine, Rifampin, Phenytoin) Or CYP3A4 Inducers (E.G. Nafcillin, Nevirapine). Serum Levels May Also Be Increased By CYP2C19 Inhibitors (E.G. Fluconazole, Fluvoxamine, Omeprazole) Or CYP3A4 Inhibitors (E.G. Azole Antifungals, Clarithromycin). May Increase Serum Levels Of Desipramine Or Metoprolol. Increased Risk Of Serotonin Syndrome When Used With Linezolid Or Sibutramine. Escitalopram May Enhance The Sedative Effects Of Alcohol. Potentially Fatal: Concomitant Administration With MAOIs May Lead To Serious Or Fatal Reactions; Should Not Be Started Until At Least 2 Wk After Stopping Escitalopram Or Vice Versa. Moclobemide May Increase The Risk Of Serotonin Syndrome.
Contraindications of GB-Cita Plus:
Concomitant Use With Or Within 2 Wk Of MAOI Withdrawal.
Mechanism of Action of GB-Cita Plus:
Escitalopram Selectively Inhibits CNS Neuronal Re-Uptake Of Serotonin (5-HT) And Potentiates Serotonergic Activity. It Has Minimal Effects On Norepinephrine And Dopamine Neuronal Re-Uptake. Onset: 1-2 Wk. Absorption: Readily Absorbed From The GI Tract (Oral). Distribution: Protein-Binding: 56%. Metabolism: Hepatic; Converted To Metabolites. Excretion: Urine (As Unchanged Drug); 27-32 Hr (Elimination Half-Life).
Special Precautions for GB-Cita Plus:
History Of Mania Or Seizure Disorders; Work Requiring Mental Alertness; Renal And Hepatic Impairment; Pregnancy, Lactation; Withdraw Gradually. Children And Adolescents <18 Yr